Irphan Gaslightwala1, Edmund J Bini. 1. Division of Gastroenterology, VA New York Harbor Healthcare System, 423 East 23rd Street, New York, NY 10010, USA.
Abstract
BACKGROUND/AIMS: Although steatosis is strongly associated with hepatitis C virus (HCV) infection, little is known about this finding in patients coinfected with human immunodeficiency virus (HIV) and HCV. The aims of the present study were to determine the prevalence and severity of steatosis in HIV/HCV coinfected patients. METHODS: Consecutive patients undergoing liver biopsy were prospectively identified and were interviewed to obtain detailed demographic and clinical data. Steatosis was scored according to the percentage of hepatocytes involved: 0 (none), 1 (<33%), 2 (33-66%), or 3 (>66%); fibrosis was scored on a scale from 0 to 4. RESULTS: A total of 708 patients were enrolled, including 154 with HIV/HCV coinfection and 554 with HCV monoinfection. Steatosis of any grade (72.1 vs. 52.0%, P<0.001), grade 2/3 steatosis (48.1 vs. 20.2%, P<0.001), and stage 3/4 fibrosis (43.5 vs. 30.0%, P=0.002) were significantly more common in coinfected patients. Compared to HCV monoinfected subjects, HIV/HCV coinfection was associated with a significantly increased odds of steatosis of any grade (OR=3.21; 95% CI, 1.84-5.60) and grade 2/3 steatosis (OR=5.63; 95% CI, 3.05-10.36) after adjusting for potential confounding variables. Among coinfected patients, the fibrosis progression rate increased in a linear fashion with the grade of steatosis. CONCLUSIONS: Steatosis is more common and more severe in HIV/HCV coinfected patients than in those with HCV monoinfection.
BACKGROUND/AIMS: Although steatosis is strongly associated with hepatitis C virus (HCV) infection, little is known about this finding in patients coinfected with human immunodeficiency virus (HIV) and HCV. The aims of the present study were to determine the prevalence and severity of steatosis in HIV/HCV coinfectedpatients. METHODS: Consecutive patients undergoing liver biopsy were prospectively identified and were interviewed to obtain detailed demographic and clinical data. Steatosis was scored according to the percentage of hepatocytes involved: 0 (none), 1 (<33%), 2 (33-66%), or 3 (>66%); fibrosis was scored on a scale from 0 to 4. RESULTS: A total of 708 patients were enrolled, including 154 with HIV/HCV coinfection and 554 with HCV monoinfection. Steatosis of any grade (72.1 vs. 52.0%, P<0.001), grade 2/3 steatosis (48.1 vs. 20.2%, P<0.001), and stage 3/4 fibrosis (43.5 vs. 30.0%, P=0.002) were significantly more common in coinfected patients. Compared to HCV monoinfected subjects, HIV/HCV coinfection was associated with a significantly increased odds of steatosis of any grade (OR=3.21; 95% CI, 1.84-5.60) and grade 2/3 steatosis (OR=5.63; 95% CI, 3.05-10.36) after adjusting for potential confounding variables. Among coinfected patients, the fibrosis progression rate increased in a linear fashion with the grade of steatosis. CONCLUSIONS:Steatosis is more common and more severe in HIV/HCV coinfectedpatients than in those with HCV monoinfection.
Authors: Nancy Crum-Cianflone; Angelica Dilay; Gary Collins; Dean Asher; Richard Campin; Sheila Medina; Zach Goodman; Robin Parker; Alan Lifson; Thomas Capozza; Mary Bavaro; Braden Hale; Charles Hames Journal: J Acquir Immune Defic Syndr Date: 2009-04-15 Impact factor: 3.731
Authors: Monica A Konerman; Shruti H Mehta; Catherine G Sutcliffe; Trang Vu; Yvonne Higgins; Michael S Torbenson; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: Hepatology Date: 2014-01-16 Impact factor: 17.425
Authors: Susan M Noworolski; Phyllis C Tien; Raphael Merriman; Daniel B Vigneron; Aliya Qayyum Journal: Magn Reson Imaging Date: 2008-11-06 Impact factor: 2.546
Authors: Richard K Sterling; Melissa J Contos; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Mitchell L Shiffman; Arun J Sanyal Journal: Hepatology Date: 2008-04 Impact factor: 17.425